CN Patent

CN1342151A — 喹啉和喹喔啉化合物

Assigned to Aventis Pharmaceuticals Inc · Expires 2002-03-27 · 24y expired

What this patent protects

本发明涉及能抑制血小板衍生生长因子酪氨酸激酶和/或Lck酪氨酸激酶的喹啉/喹喔啉化合物,包含这些化合物的药物组合物,这些化合物在治疗患有或易患有涉及细胞分化、增殖、细胞外基质产生或介质释放和/或T细胞活化和增殖的疾病/病症的患者中的应用。

USPTO Abstract

本发明涉及能抑制血小板衍生生长因子酪氨酸激酶和/或Lck酪氨酸激酶的喹啉/喹喔啉化合物,包含这些化合物的药物组合物,这些化合物在治疗患有或易患有涉及细胞分化、增殖、细胞外基质产生或介质释放和/或T细胞活化和增殖的疾病/病症的患者中的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN1342151A
Jurisdiction
CN
Classification
—
Expires
2002-03-27
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.